Free Trial

Myriad Genetics (MYGN) Competitors

Myriad Genetics logo
$5.50 -0.22 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$5.50 0.00 (0.00%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MYGN vs. BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, NVAX, GERN, and RGLS

Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

Myriad Genetics vs. Its Competitors

Myriad Genetics (NASDAQ:MYGN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Myriad Genetics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

In the previous week, BioCryst Pharmaceuticals had 9 more articles in the media than Myriad Genetics. MarketBeat recorded 11 mentions for BioCryst Pharmaceuticals and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.67 beat BioCryst Pharmaceuticals' score of 0.62 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Myriad Genetics currently has a consensus price target of $14.38, suggesting a potential upside of 161.54%. BioCryst Pharmaceuticals has a consensus price target of $16.70, suggesting a potential upside of 88.06%. Given Myriad Genetics' higher possible upside, equities research analysts clearly believe Myriad Genetics is more favorable than BioCryst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13
BioCryst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.4% of Myriad Genetics shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a net margin of -10.62% compared to Myriad Genetics' net margin of -12.20%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-12.20% -4.95% -3.39%
BioCryst Pharmaceuticals -10.62%N/A -11.06%

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$837.60M0.61-$127.30M-$1.12-4.91
BioCryst Pharmaceuticals$450.71M4.12-$88.88M-$0.26-34.15

Summary

BioCryst Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYGN vs. The Competition

MetricMyriad GeneticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$527.26M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-4.918.0519.5820.23
Price / Sales0.61296.11442.27127.79
Price / Cash5.7242.7337.5058.41
Price / Book0.717.748.085.60
Net Income-$127.30M-$54.96M$3.16B$248.43M
7 Day Performance-1.79%6.04%3.77%5.15%
1 Month Performance5.16%4.47%3.90%7.62%
1 Year Performance-78.12%6.12%34.22%21.56%

Myriad Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYGN
Myriad Genetics
4.4646 of 5 stars
$5.50
-3.8%
$14.38
+161.5%
-77.3%$527.26M$837.60M-4.912,700News Coverage
BCRX
BioCryst Pharmaceuticals
4.4896 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+39.8%$1.87B$450.71M-34.46530
FOLD
Amicus Therapeutics
4.0513 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-37.7%$1.76B$528.29M-63.66480News Coverage
Analyst Revision
CLDX
Celldex Therapeutics
3.0904 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-39.6%$1.35B$7.02M-7.54150Positive News
INVA
Innoviva
4.3115 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+15.5%$1.26B$358.71M-19.89100Positive News
DVAX
Dynavax Technologies
4.3803 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-1.5%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5436 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-28.6%$1.14B$297.60M37.40400Negative News
OPK
OPKO Health
4.6588 of 5 stars
$1.32
flat
$2.75
+108.3%
+7.0%$1.05B$713.10M-18.852,997News Coverage
Positive News
Analyst Upgrade
NVAX
Novavax
4.4924 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-40.5%$1.02B$682.16M2.381,990
GERN
Geron
3.3134 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-68.6%$898.06M$76.99M-6.7170News Coverage
Analyst Forecast
Gap Down
RGLS
Regulus Therapeutics
1.5997 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830

Related Companies and Tools


This page (NASDAQ:MYGN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners